SCHEMBL2608307

SCHEMBL2608307

Cc1ccc(/C=N/N=C/c2ccc(C)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 1.00
RAB9A P51151 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
GRIN2D O15399 3/20 0.64
GRIN3B O60391 3/20 0.64
GRIN1 Q05586 3/20 0.64
GRIN2A Q12879 3/20 0.64
GRIN2B Q13224 3/20 0.64
GRIN2C Q14957 3/20 0.64
GRIN3A Q8TCU5 3/20 0.64
ALDH1A1 P00352 2/20 0.55
MAPT P10636 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.52
LMNA P02545 1/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
CYP2A6 P11509 1/20 0.50
RRM1 P23921 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11743247 1.00 NPC1 (1.00) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL7793323 0.88 NPC1 (0.77) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL19036447 0.88 NPC1 (0.77) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL7793321 0.88 NPC1 (0.77) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL10942218 0.86 NPC1 (0.74) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL22995747 0.84 NPC1 (0.71) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL22198249 0.84 SMN1; SMN2 (0.71) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL22198250 0.84 NPC1 (0.71) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL7793269 0.82 NPC1 (0.68) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B
SCHEMBL7793264 0.82 NPC1 (0.68) NPC1RAB9ASMN1; SMN2GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220325053-A1 METHOD FOR THE SYNTHESIS OF A TWO-DIMENSIONAL OR QUASI-TWO-DIMENSIONAL POLYMER FILM, THE TWO-DIMENSIONAL OR QUASI-TWO-DIMENSIONAL POLYMER FILM AND THE USE Technische Universität Dresden (DE) 2022-10-13 US disclosed
US-11345180-B2 Display medium for assessment and method for manufacturing same ZEON CORPORATION (JP) 2022-05-31 US disclosed
US-20210393810-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF HTA Co., Ltd. (CN) 2021-12-23 US disclosed
WO-2021028429-A1 METHOD FOR THE SYNTHESIS OF A TWO-DIMENSIONAL OR QUASI-TWO-DIMENSIONAL POLYMER FILM, THE TWO-DIMENSIONAL OR QUASI-TWO-DIMENSIONAL POLYMER FILM AND THE USE Technische Universität Dresden (DE) 2021-02-18 WO disclosed
WO-2020140924-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO AΒ PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF 原子高科股份有限公司 2020-07-09 WO disclosed
EP-3502755-A1 DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME Zeon Corporation (JP) 2019-06-26 EP disclosed
US-20190184732-A1 DISPLAY MEDIUM FOR ASSESSMENT AND METHOD FOR MANUFACTURING SAME ZEON CORPORATION (JP) 2019-06-20 US disclosed
US-8871977-B2 Asymmetric azine compound and method for producing the same ZEON CORPORATION (JP) 2014-10-28 US disclosed
EP-2143710-B1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL ZEON CORP (JP) 2014-07-09 EP disclosed
US-8454857-B2 Polymerizable liquid crystal compounds, polymerizable liquid crystal compositions, liquid crystalline polymers and optically anisotropic materials ZEON CORPORATION (JP) 2013-06-04 US disclosed
US-20110233464-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER AND FILM FUJIFILM CORPORATION (JP) 2011-09-29 US disclosed
US-20110233464-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLYMER AND FILM FUJIFILM CORPORATION (JP) 2011-09-29 US disclosed
US-20110144379-A1 ASYMMETRIC AZINE COMPOUND AND METHOD FOR PRODUCING THE SAME ZEON CORPORATION (JP) 2011-06-16 US disclosed
US-20110140041-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS ZEON CORPORATION (JP) 2011-06-16 US disclosed
US-20110140041-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS ZEON CORPORATION (JP) 2011-06-16 US disclosed
EP-2295477-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTAL POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS Zeon Corporation (JP) 2011-03-16 EP disclosed
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE ZEON CORPORATION (JP) 2010-10-14 US disclosed
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE ZEON CORPORATION (JP) 2010-10-14 US disclosed
EP-2143710-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL ZEON CORPORATION (JP) 2010-01-13 EP disclosed
US-3939147-A Novel 1,2-diaza-1,5,9-cyclo dodecatrienes and 1,2-diaza-1-cyclododecenes CIBA-GEIGY CORPORATION (US) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110140041-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS, LIQUID CRYSTALLINE POLYMERS AND OPTICALLY ANISOTROPIC MATERIALS CCNB1, CCNT1, CCNB2 NPC1 1382/4885RAB9A 3375/4885SMN1; SMN2 3351/4885
US-20100258764-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE LEO1, ZYX, CCNT1 NPC1 2081/4885RAB9A 3857/4885SMN1; SMN2 4179/4885
US-20110144379-A1 ASYMMETRIC AZINE COMPOUND AND METHOD FOR PRODUCING THE SAME ADH5, ADH1C, ADH1A NPC1 4099/4885RAB9A 1006/4885SMN1; SMN2 4347/4885
US-20210393810-A1 DIHYDRAZONE COMPOUNDS HAVING HIGH AFFINITY TO A BETA PROTEIN AND TAU PROTEIN, DERIVATIVES THEREOF AND USE THEREOF MAPT, APP, PSEN1 NPC1 2250/4885RAB9A 2536/4885SMN1; SMN2 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.